Liposomal delivery of camptothecins

Pharmaceutical Science and Technology Today

Volumn 3, Issue 6, 2000, Pages 205-209

  Emerson, David L ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; IRINOTECAN; LIPOSOME; LURTOTECAN; TOPOTECAN;

CANCER; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG MECHANISM; HUMAN; REVIEW; TISSUE DISTRIBUTION;

EID: 0034213232     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1461-5347(00)00268-6     Document Type: Review

References (36)

1. Wall M.E.et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88:1966;3888-3890.
2. Gottlieb J.A.et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 54:1970;461-470.
3. Muggia F.M.et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. 56:1972;515-521.
4. Moertel C.G.et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56:1972;95-101.
5. Hsiang Y.H.et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:1985;14873-14878.
6. Mattern M.et al. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res. 47:1985;1793-1797.
7. Hsiang Y.H., Liu L.P. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726.
8. Rothenberg M.L. Topoisomerase I inhibitors: review and update. Ann. Oncol. 8:1977;839-855.
9. de Jonge M.J.A.et al. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer Treat. Rev. 24:1998;205-220.
10. Mi Z.et al. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry. 34:1995;13722-13728.
11. Burke T.G.et al. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm. Sci. 84:1995;518-519.
12. Mi Z., Burke T.G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry. 33:1994;10325-10336.
13. Mi Z., Burke T.G. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry. 33:1994;12540-12545.
14. Burke T.G., Mi Z. Preferential binding of the carboxylate form of camptothecin by human albumin. Anal. Biochem. 212:1993;285-287.
15. Burke T.G., Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem. 37:1994;40-46.
16. Sugarman S.M.et al. Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chemother. Pharmacol. 37:1996;531-538.
17. Burke T.G.et al. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry. 32:1993;5352-5364.
18. Burke T.G.et al. Liposomal stabilization of camptothecin's lactone ring. J. Am. Chem. Soc. 114:1992;8318-8319.
19. Burke T.G., Gao X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcoline. J. Pharm. Sci. 83:1994;967-969.
20. Subramanian D., Muller M.T. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncol. Res. 7:1995;461-469.
21. Madden T.D.et al. Encapsulation of topotecan in lipid-based carrier systems. Evaluation of drug stability and plasma elimination in a murine model, and comparison of antitumor efficacy against murine L1210 and B16. Proc. Am. Soc. Clin. Oncol. 17:1998;196a.
22. Sadzuka Y.et al. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett. 127:1998;99-106.
23. Sadzuka Y.et al. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn. J. Cancer Res. 90:1999;226-232.
24. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta. 1113:1992;171-199.
25. Wanders J.et al. Phase II studies with GI147211 (GW211) in small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 17:1998;474a.
26. Sessa C.et al. A phase II study with GI147211 (GW211) in small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 17:1998;254a.
27. Chavan A.J.et al. A comparative study of the human blood stability characteristics of remote-loaded liposomal carriers containing clinically-relevant camptothecins. Proc. Am. Assoc. Cancer Res. 40:1999;417a.
28. Emerson D.L.et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res. 55:1995;603-609.
29. Lynam E.et al. Camptothecin analogue efficacy in vitro: effect of liposomal encapsulation of GI147211C (NX211). Drug Delivery. 6:1999;51-62.
30. Colbern G.T.et al. Encapsulation of the topoisomerase I inhibitor GI 147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res. 4:1998;3077-3082.
31. Emerson D.L.et al. NX-211, a liposomal formulation of lurtotecan demonstrates enhanced pharmacokinetic and antitumor activity. Proc. Am. Assoc. Cancer Res. 39:1998;278a.
32. Hamilton M.et al. Pharmacokinetics, distribution, and toxicology of NX211 (liposomal lurtotecan) in mice and rats. Proc. Am. Soc. Clin. Oncol. 18:1999;177a.
33. Desjardins J.P.et al. Biodistribution of NX 211, liposomal GI147211, in tumor bearing mice. Proc. Am. Assoc. Cancer Res. 41:2000;702-703.
34. Wu N.Z.et al. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53:1993;3765-3770.
35. Tomkinson B.E.et al. In vivo evaluation of NX 211 in combination with cisplatin, 5-FU, and paclitaxel. Proc. Am. Assoc. Cancer Res. 41:2000;144a.
36. Gelmon K.A.et al. Phase I study of NX 211 (liposomal lurtotecan) given as an intravenous infusion on days 1, 2, & 3 every 3 weeks in patients (PTS) with solid tumors - AN NCIC Clinical Trials Group. Proc. Am. Assoc. Cancer Res. 41:2000;610a.